| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H28O2 |
| Molecular Weight | 312.4458 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C
InChI
InChIKey=JWAHBTQSSMYISL-MHTWAQMVSA-N
InChI=1S/C21H28O2/c1-13(22)20(2)11-9-19-18-6-4-14-12-15(23)5-7-16(14)17(18)8-10-21(19,20)3/h12,18-19H,4-11H2,1-3H3/t18-,19+,20-,21+/m1/s1
| Molecular Formula | C21H28O2 |
| Molecular Weight | 312.4458 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Demegestone, a norprogesterone derivative, is a progesterone receptor agonist that was previously used to treat luteal insufficiency. It was marketed in France as Lutionex, but has since been discontinued. Demegestone has also been studied in combination with estrogens as an oral contraceptive and treatment for infertility. Demegestone did not exercise androgenic activity. Demegestone is the potent inhibitor of estrone sulfatase activity.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
In order to evaluate the safety and effectiveness of a low-dose progestagen oral contraceptive, 46 women were administered 0.25 mg daily of a synthetic gestagen, Demegestone, for 1-12 months for a total of 189 cycles. The pill was found to be safe and completely effective with no pregnancies occurring in the study group. The length of the bleeding cycle was found to be prolonged under this treatment, to an average of 40 days
Route of Administration:
Oral
